Read time: 5 minutes Plasmid DNA serves a variety of purposes, from critical starting material for proteins, mRNA, viral vectors, and drug substances. Below, Dr. Emma Bjorgum, the Vice President of Client Services of the DNA Business Unit at Aldevron and an expert in...
Read time: 11 minutes Interviewee: Adam Crowe (PhD), Sr Manager of Analytical Development, Cytiva A few years ago, it was discovered that messenger RNA (mRNA) encapsulated in lipid nanoparticles (LNPs) could result in mRNA adducts due to the breakdown products of...
Read time: 8 minutes Lipid-based nanoparticles (LNPs) are effective non-viral vectors for delivering messenger RNA (mRNA) products or other drug substances. In a recent webinar, Jérémie Parot (PhD), Research Scientist at SINTEF Industry, demonstrated the robust and...
Read time: 6 minutes In a recent webinar, available on demand, Jingtao Zhang (PhD), Scientific Director, and Daniel Turner, Scientist at Catalent® Pharma Solutions, presented their approaches to addressing stability challenges of mRNA-based products. In the...
Read time: 10 minutes In 1998, the US Food and Drug Administration (FDA) approved fomivirsen as the first therapeutic oligonucleotide therapeutic. This approval marked a revolution of mechanism of action discovered decades before finally coming to fruition. Since...
Read time: 7 minutes Prime editing (PE) is a next-generation gene editing technology that utilizes a Cas9 protein fused to a prime editing guide ribonucleic acid (pegRNA) to achieve high CRISPR/Cas9 editing efficiency and precision. However, the length requirement of...
Read time: 6 minutes Certain next-gen vaccines and gene therapy applications rely on the usage of adeno-associated viruses (AAV) as a delivery vehicle. To ensure the safety and efficacy of viral vector drugs, multiple critical quality attributes (CQAs) need to be well...
Read Time: 7 minutes Interviewee: Jane Luo (PhD), Senior Scientist, SCIEX Lipid nanoparticles (LNPs) are widely used vehicles for mRNA-based therapeutics and vaccines. However, ionizable lipids used in LNPs can be susceptible to N-oxide impurities that can cause...
Read Time: 9 minutes Lipid nanoparticles (LNPs) are widely used vehicles for messenger RNA (mRNA)-based therapeutics and vaccines. However, ionizable lipids used in LNPs can be susceptible to N-oxide impurities that can cause functional loss of the mRNA cargo. In a...
Read time: 9 minutes Currently, there are 3 main types of in vitro transcribed (IVT) RNA drugs, encapsulated in lipid nanoparticles (LNPs). Two of these—conventional messenger RNA (mRNA) and base-modified mRNA (bmRNA), which incorporates chemically modified...